We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Combination Therapy Is More Effective in Stopping Tumor Growth

By LabMedica International staff writers
Posted on 18 Nov 2008
Cancer researchers have found that treating tumors to inhibit the activity of vascular endothelial growth factor (VEGF) to prevent development of new blood vessels is less effective than combining antiangiogenesis treatment with classical chemotherapy.

Investigators at the University of California, San Diego (La Jolla, CA, USA) worked with a line of mice that had been genetically engineered to lack the gene for VEGF. More...
These animals served as a model emulating the results of antiangiogenesis treatment. The absence of VEGF activity made it easier to study the effects of another growth factor, platelet-derived growth factor (PDGF).

Results published in two papers published in the November 9, 2008, online edition of the journal Nature revealed that VEGF in large quantities, as often found in tumor cells, acted to inhibit the activity of PDGF. This prevented PDGF from activating cells called pericytes that surround and stabilize blood vessels, explaining why tumor blood vessels are often immature and poorly functional.

Inhibition of VEGF promotes PDGF activity, which in turn allows tumor blood vessels to mature. Initially this stimulates growth of the tumor, but increased blood flow then facilitates the transport of chemotherapeutic agents into the tumor.

"We have discovered that when antiangiogenesis drugs are used to lower the level of VEGF within a tumor, it is not so much a reduction in the endothelial cells and losing blood vessels as it is an activation of the tumor blood vessels supporting cells,” explained senior author Dr. David Cheresh, professor of pathology at the University of California, San Diego. "This enables vessels to mature, providing a conduit for better drug delivery to the tumor. While the tumors initially get larger, they are significantly more sensitive to chemotherapeutic drugs. It means that chemotherapy could be timed appropriately. We could first stabilize the blood vessels, and then come in with chemotherapy drugs that are able to treat the cancer.”

"It is not just about the therapy, but also what the host does in response to the cancer that makes a difference whether a tumor lives or dies, and if it is susceptible to a drug or not. We can change the host response to the cancer, which is otherwise resistant, and make the vessels more mature, temporarily increasing blood flow to the cancer. We may be giving the right drugs, but we may not be giving them in the right order. We are just beginning to understand how it works,” said Dr. Cheresh.

Related Links:

University of California, San Diego


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.